Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management

Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel category of oral antidiabetic drugs that suppress renal glucose reabsorption and increase renal glucose excretion, thus lowering plasma glucose levels. This unique mechanism of SGLT2i action is insulin independent, thus improving glycemi...

Bibliografski detalji
Glavni autori:	Katsiki, N, Mikhailidis, D, Theodorakis, M
Format:	Journal article
Izdano:	Bentham Science Publishers 2017

Slični predmeti

Regulation of the intestinal sodium/ glucose cotransporter SGLT1 in health and disease
od: Stearns, A
Izdano: (2009)

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
od: Vasilakou, D, i dr.
Izdano: (2013)

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
od: Fletcher, RA, i dr.
Izdano: (2024)

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
od: McGovern, A, i dr.
Izdano: (2017)

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol)
od: McGovern, A, i dr.
Izdano: (2017)

Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis
od: Patel, SM, i dr.
Izdano: (2024)

S0859, an N-cyanosulphonamide inhibitor of sodium-bicarbonate cotransport in the heart.
od: Ch'en, F, i dr.
Izdano: (2008)

Disparities in prescribing of sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP-4 inhibitors in people with Type 2 diabetes and chronic kidney disease (CKD)
od: Shah, S, i dr.
Izdano: (2018)

In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
od: Ng, SYA, i dr.
Izdano: (2020)

Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy plus /- oral agents in type 2 diabetes
od: Matthews, DR, i dr.
Izdano: (2012)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
od: Herrington, W, i dr.
Izdano: (2022)

Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach
od: Theodorakis, M, i dr.
Izdano: (2016)

Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes
od: Marjot, T, i dr.
Izdano: (2019)

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study
od: Chou, OHI, i dr.
Izdano: (2024)

SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens
od: Chung, YJ, i dr.
Izdano: (2021)

UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (sglt-2) inhibition in adults with kidney disease 2023 update
od: Roddick, AJ, i dr.
Izdano: (2023)

Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans
od: Kondo, H, i dr.
Izdano: (2019)

Systematic review and meta-analysis of the efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus
od: Tsapas, A, i dr.
Izdano: (2012)

In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality
od: Zhu, D, i dr.
Izdano: (2024)

A national audit of SGLT2 use in England
od: McGovern, A, i dr.
Izdano: (2017)

Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men
od: Rådholm, K, i dr.
Izdano: (2019)

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors
od: Herrington, WG, i dr.
Izdano: (2021)

The effect of sodium‐glucose co‐transporter 2 inhibitors on outcomes after cardiac resynchronization therapy
od: Bray, JJ, i dr.
Izdano: (2024)

Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
od: Hinton, W, i dr.
Izdano: (2020)

Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
od: Vergari, E, i dr.
Izdano: (2019)

Development of an in silico model to extrapolate whole body glucose - insulin homeostasis by altering tissue specific effects, simulation of SGLT-2 inhibition in type 2 diabetes
od: Hill, N, i dr.
Izdano: (2009)

Functional diversity of electrogenic sodium-bicarbonate cotransport in ventricular myocytes from rat, rabbit and guinea pig
od: Yamamoto, T, i dr.
Izdano: (2005)

The obstetrician's role in preventing cardiometabolic disease
od: Hirst, J, i dr.
Izdano: (2019)

Moderate alcohol intake and cardiometabolic risk in adults with type 2 diabetes: To the editor
od: Altman, D
Izdano: (2016)

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
od: Hinton, W, i dr.
Izdano: (2021)

Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
od: Vale, C, i dr.
Izdano: (2024)

Does renal function or heart failure diagnosis affect primary care prescribing for sodium-Glucose co-transporter 2 inhibitors in type 2 diabetes?
od: Hinton, W, i dr.
Izdano: (2020)

Genome-wide polygenic risk score, cardiometabolic risk factors, and type 2 diabetes mellitus in the Chinese population
od: Huang, N, i dr.
Izdano: (2023)

UP-REGULATION OF NA/K PUMPS BY LOOP DIURETICS - NONINVOLVEMENT OF NA/K/2CL COTRANSPORT
od: Murton, R, i dr.
Izdano: (1995)

How generalizable are cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors? A national database study: study protocol
od: Hinton, W, i dr.
Izdano: (2019)

Comparing the risks of new-onset gastric cancer or gastric diseases in type 2 diabetes mellitus patients exposed to SGLT2I, DPP4I or GLP1A: a population-based cohort study
od: Chou, OHI, i dr.
Izdano: (2024)

Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition
od: Kondo, H, i dr.
Izdano: (2020)

The potassium-chloride cotransporter 2 promotes cervical cancer cell migration and invasion by an ion transport-independent mechanism.
od: Wei, W, i dr.
Izdano: (2011)

Effect of the Na-K-2Cl cotransporter NKCC1 on systemic blood pressure and smooth muscle tone.
od: Garg, P, i dr.
Izdano: (2007)

The potassium-chloride cotransporter 2 promotes cervical cancer cell migration and invasion by an ion transport-independent mechanism
od: Wei, W, i dr.
Izdano: (2011)